Login to Your Account

Aerie shares climb ahead of glaucoma drug adcom

By Michael Fitzhugh
Staff Writer

Wednesday, October 11, 2017

Aerie Pharmaceuticals Inc.'s claims about the efficacy of its triple-acting glaucoma drug, Rhopressa, earned uncomplicated support from FDA briefing docs published ahead of the agency's Friday DODAC meeting.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription